Protocol logistics

Cold chain: what a temperature excursion does to a peptide

This page describes degradation mechanisms and the published excursion literature. It prescribes no storage temperature, no duration and no procedure, and does not tell you whether any product that got warm or froze is usable — that is a question for the manufacturer's own labelling and for the pharmacy that dispensed it.

What actually degrades

Temperature does not damage a peptide directly. It changes the rate of chemical and physical processes that were going to happen anyway. The protein-stability literature groups them into two families, and the distinction matters because they produce different failures.⁴

• Chemical instability — covalent changes to the molecule. Deamidation of asparagine and glutamine residues, oxidation of methionine and cysteine, hydrolysis of the backbone, disulfide scrambling, beta-elimination.
• Physical instability — changes to the molecule's state rather than its covalent structure. Unfolding, adsorption to surfaces, self-association, aggregation and precipitation.⁴

The two are coupled. A partly unfolded molecule exposes residues that were previously buried, which accelerates the chemical routes; chemical modification in turn destabilises the folded state. That interrelationship is one of the things the stability literature is explicitly about, and it is why a single number for "degradation rate" is a simplification even in a controlled study.⁴

Why freezing is the underrated excursion

The instinct is that cold is safe and colder is safer. For proteins in solution this is wrong in a specific, well-characterised way. Freezing is not simply the low end of a temperature axis; it is a phase change that creates several new stresses at once.⁵

• Freeze concentration. As water crystallises, everything dissolved in it is forced into a shrinking volume of remaining liquid at far higher concentration than the original solution.
• Ice-water interfaces. New surface area appears, and proteins adsorb to and can unfold at those interfaces.
• pH shift. Buffer components can crystallise at different points during freezing, moving the pH of the unfrozen fraction away from where it started.
• Cold denaturation and cryoconcentration effects on the molecule's folded state.⁵

The practical consequence is the important one: damage from freezing is frequently not visible. A solution that froze and thawed can look exactly like one that did not, and the aggregates most likely to have formed are often sub-visible. Appearance is not a test.⁵

Freezing is common in supply chains that are supposed to be cold

This is not a hypothetical risk added for completeness. A systematic review of the vaccine cold chain found that freezing temperatures were frequently encountered across studies, in both storage and transport, including in high-income settings and in shipments that were nominally temperature-controlled.⁶

That literature exists because vaccines are freeze-sensitive, monitored, and consequential enough to have generated decades of published field data. WHO publishes practical guidance on monitoring temperatures in that supply chain for the same reason. There is no equivalent body of field data for anything sold as a research peptide.⁶¹⁰

What the heat literature actually found

The most-cited recent work on heat exposure for an injectable peptide product is a study of several insulin types under oscillating tropical ambient temperatures, which reported that bioactivity of samples stored at oscillating ambient temperature during the usage period was comparable to samples held at the reference refrigerated condition of 2–8 °C.⁷

Read what that establishes and what it does not. It establishes something about specified insulin formulations, in their own containers, over a stated usage period, under a defined oscillation profile. It does not establish anything about a different molecule, a different formulation, a different container, a longer period, or a constant high temperature. A Cochrane review of thermal stability and storage of human insulin exists precisely because summarising this area responsibly requires that much care.⁷⁸

How the regulated world handles excursions

Stability guidance defines how a product's storage statement is generated: defined batches, in the marketed container-closure system, at defined conditions, tested at defined intervals — with additional expectations for biotechnological and biological products, which are more sensitive to environmental conditions than small molecules.²³

WHO's model guidance for time- and temperature-sensitive pharmaceutical products describes the distribution half of the same problem: qualified shipping systems, temperature monitoring, defined responses when a monitored shipment goes out of range. The recurring principle is that an excursion is assessed against product-specific stability data, by whoever holds that data. Without the data there is no assessment, only a judgement call.¹

That is why the honest answer to "my package arrived warm, is it still good?" for an approved product is: ask the manufacturer or the dispensing pharmacy, because they can consult the stability file. For an unapproved product there is no stability file and no one to ask.¹⁹

The excursion problem in this specific market

FDA has stated that it received complaints that certain compounded GLP-1 products arrived warm or with inadequate ice packs to maintain the recommended storage temperature. That is a documented, market-specific observation rather than an extrapolation, and it identifies the leg of the chain a buyer has least visibility into: the one between dispatch and doorstep.⁹

It also identifies why a certificate of analysis cannot help here. Testing happened before shipping. Whatever a package experienced in transit is a later event that no earlier document describes.⁹

What a person can actually do

Given the above, the useful response to an excursion is not a judgement. It is a record. An excursion is an observable event even when its consequences are not, and a written one can be raised with a pharmacist or clinician later; an unwritten one cannot.

• What was observed — warm to the touch on arrival, ice packs fully melted, frozen solid, condensation in the container.
• When, as a full timestamp with timezone context, and for how long if that is knowable.
• Where the item was between events, and what the monitoring was, if any.
• The lot number of the affected container, so the event attaches to an identifiable object rather than to a memory.
• What the labelling for that specific product says about storage, transcribed rather than paraphrased.¹¹⁰

An insulated case transports containers. It does not qualify as a shipping system in the sense WHO's guidance means, does not monitor anything unless it has a monitor in it, and preserves nothing on its own. If it keeps a label and a lot number physically next to the container they describe, the benefit is to the record — which is the only claim made for it here.